Th17 cells: A new target in kidney disease research.

IF 4.3 4区 医学 Q2 IMMUNOLOGY
International Reviews of Immunology Pub Date : 2024-01-01 Epub Date: 2024-03-05 DOI:10.1080/08830185.2024.2321901
Tao Zhang, Hongyan Huo, Yinghui Zhang, Jie Tao, Junzheng Yang, Xianglu Rong, Yiqi Yang
{"title":"Th17 cells: A new target in kidney disease research.","authors":"Tao Zhang, Hongyan Huo, Yinghui Zhang, Jie Tao, Junzheng Yang, Xianglu Rong, Yiqi Yang","doi":"10.1080/08830185.2024.2321901","DOIUrl":null,"url":null,"abstract":"<p><p>Type 17 T helper (Th17) cells, which are a subtype of CD4<sup>+</sup> T helper cells, secrete pro-inflammatory cytokines such as IL-17A, IL-17F, IL-21, IL-22, and GM-CSF, which play crucial roles in immune defence and protection against fungal and extracellular pathogen invasion. However, dysfunction of Th17 cell immunity mediates inflammatory responses and exacerbates tissue damage. This pathological process initiated by Th17 cells is common in kidney diseases associated with renal injury, such as glomerulonephritis, lupus nephritis, IgA nephropathy, hypertensive nephropathy, diabetic kidney disease and acute kidney injury. Therefore, targeting Th17 cells to treat kidney diseases has been a hot topic in recent years. This article reviews the mechanisms of Th17 cell-mediated inflammation and autoimmune responses in kidney diseases and discusses the related clinical drugs that modulate Th17 cell fate in kidney disease treatment.</p>","PeriodicalId":14333,"journal":{"name":"International Reviews of Immunology","volume":null,"pages":null},"PeriodicalIF":4.3000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Reviews of Immunology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/08830185.2024.2321901","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/3/5 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Type 17 T helper (Th17) cells, which are a subtype of CD4+ T helper cells, secrete pro-inflammatory cytokines such as IL-17A, IL-17F, IL-21, IL-22, and GM-CSF, which play crucial roles in immune defence and protection against fungal and extracellular pathogen invasion. However, dysfunction of Th17 cell immunity mediates inflammatory responses and exacerbates tissue damage. This pathological process initiated by Th17 cells is common in kidney diseases associated with renal injury, such as glomerulonephritis, lupus nephritis, IgA nephropathy, hypertensive nephropathy, diabetic kidney disease and acute kidney injury. Therefore, targeting Th17 cells to treat kidney diseases has been a hot topic in recent years. This article reviews the mechanisms of Th17 cell-mediated inflammation and autoimmune responses in kidney diseases and discusses the related clinical drugs that modulate Th17 cell fate in kidney disease treatment.

Th17 细胞:肾病研究的新目标
17 型 T 辅助细胞(Th17)是 CD4+ T 辅助细胞的一种亚型,能分泌促炎细胞因子,如 IL-17A、IL-17F、IL-21、IL-22 和 GM-CSF,在免疫防御和抵御真菌及细胞外病原体入侵方面发挥重要作用。然而,Th17 细胞免疫功能失调会介导炎症反应并加剧组织损伤。在肾小球肾炎、狼疮性肾炎、IgA 肾病、高血压肾病、糖尿病肾病和急性肾损伤等与肾损伤相关的肾脏疾病中,Th17 细胞引发的这一病理过程十分常见。因此,靶向 Th17 细胞治疗肾脏疾病是近年来的热门话题。本文回顾了肾脏疾病中Th17细胞介导的炎症和自身免疫反应的机制,并探讨了调节Th17细胞命运的相关临床药物在肾脏疾病治疗中的应用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
11.00
自引率
4.00%
发文量
24
期刊介绍: This review journal provides the most current information on basic and translational research in immunology and related fields. In addition to invited reviews, the journal accepts for publication articles and editorials on relevant topics proposed by contributors. Each issue of International Reviews of Immunology contains both solicited and unsolicited review articles, editorials, and ''In-this-Issue'' highlights. The journal also hosts reviews that position the authors'' original work relative to advances in a given field, bridging the gap between annual reviews and the original research articles. This review series is relevant to all immunologists, molecular biologists, microbiologists, translational scientists, industry researchers, and physicians who work in basic and clinical immunology, inflammatory and allergic diseases, vaccines, and additional topics relevant to medical research and drug development that connect immunology to disciplines such as oncology, cardiovascular disease, and metabolic disorders. Covered in International Reviews of Immunology: Basic and developmental immunology (innate and adaptive immunity; inflammation; and tumor and microbial immunology); Clinical research (mechanisms of disease in man pertaining to infectious diseases, autoimmunity, allergy, oncology / immunology); and Translational research (relevant to biomarkers, diagnostics, vaccines, and drug development).
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信